35건 · 관련도순
Writes or reviews a pre-analysis plan before data collection: registry choice (OSF, AEA, AsPredicted, registered reports), locked models and decision rules, code run on simulated data, contingencies, and deviation records. Use when drafting or auditing a pre-registration or PAP, choosing a registry, or handling a deviation.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Write or rewrite prose so it sounds like a human wrote it — not a frontier model. Named in homage to Rabindranath Tagore, whose prose carried what frontier models reach for and miss: a point of view, specificity over abstraction, and restraint over puffery. Merges two complementary approaches: a 29-pattern catalog of AI tells (from humanizer) plus an 8-rule operating system with an 8-dimension scoring gate (extending stop-slop). Use when drafting, editing, or reviewing any prose: essays, posts, docs, reports, emails. Detects and removes inflated symbolism, promotional language, superficial -ing analyses, vague attributions, em dash overuse, rule of three, AI vocabulary, passive voice, negative parallelisms, filler phrases, inanimate-verb constructions, narrator-from-a-distance voice, and metronomic rhythm. Adds back the things AI writing usually lacks: point of view, stakes, specificity, restraint, varied rhythm, and trust in the reader.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Marketing analytics and data-driven optimization for B2B SaaS campaigns. Use this skill when analyzing marketing performance, optimizing conversion rates, running A/B tests, conducting customer research, creating marketing dashboards, building attribution models, analyzing funnel metrics, or storytelling with data. Also triggers on: marketing ops, performance analytics, CRO, A/B testing, data storytelling, customer insights, tracking plan, event taxonomy, UTM taxonomy, GA4 audit, consent mode, instrumentation contract, sample size calculation, minimum detectable effect, test duration, not enough traffic to A/B test, statistical significance, Bayesian vs frequentist, sample ratio mismatch, experiment feasibility, martech stack, marketing tech stack audit, tool consolidation, build vs buy, vendor evaluation, shadow IT tools, ESP/CRM/platform migration, switching cost, cutover plan, suppression list migration, data portability, customer interviews, survey design, sampling frame, non-response bias, how many people should I interview, thematic saturation, voice of customer, jobs-to-be-done, buyer persona research, is this finding real, data enrichment, which enrichment provider should we buy, waterfall enrichment, contact data quality, match rate, our list data is bad, email verification, catch-all domain, accept-all, bounce rate from bad data, B2B data decay, how often should we re-verify contacts, ZoomInfo vs Apollo vs Clearbit evaluation, cost per usable record, where did this list come from, GDPR Article 14 notice, purchased list compliance, suppression screening, TAM list building, demand planning, marketing plan, how many leads do we need, what pipeline target should marketing carry, funnel model, top-down vs bottom-up plan, plan of record, annual marketing planning, quarterly planning, pipeline coverage we have to create, sales cycle lag, our leads cannot close this quarter, carry-in pipeline, scenario planning, conservative moderate aggressive forecast, stretch target, reforecast, re-forecast triggers, assumption register, capacity ceiling, addressable audience ceiling, marginal cost per lead, blended CPL is wrong, we missed plan and nobody knows why, AI policy for the marketing team, AI governance, AI acceptable use policy, which AI tools are we allowed to use, can I paste customer data into ChatGPT, shadow AI, AI use register, human review of AI output, when can we stop reviewing every AI draft, can the agent send on its own, the AI made a mistake now what, pull back AI autonomy, AI evals, our AI vendor changed the model, AI output went out wrong, prompt injection, can our AI read prospect replies safely, lethal trifecta, the AI leaked internal notes, turn off auto-generated ad assets, auto-applied recommendations, AI literacy training, EU AI Act Article 4, duplicate records in the CRM, dedupe before import, which value wins in a merge, CRM cleanup.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Resolve CodeRabbit review feedback on a GitHub pull request. Collects every open CodeRabbit finding (inline threads, plus the nitpick and outside-diff findings packed into review bodies), judges and fixes each one against the real code with subagents, unifies fixes that share a pattern, commits locally, asks before pushing, then shows every reply draft linked to its finding and posts only on approval. Runs only on top-tier models. Use on "resolve the CodeRabbit feedback", "address coderabbit comments", "answer the rabbit", "fix what CodeRabbit flagged on
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Django Redis caching with django-cacheops. This skill should be used when implementing caching, adding cache invalidation, optimizing API performance, modifying models that affect cached data, or debugging cache-related issues in the Django backend.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Create, revise, and validate publication-ready academic paper figures and tables. Use for LaTeX tables, related-work comparison tables, result tables, notation/dataset/taxonomy tables, precise source-data-driven experiment plots from CSV/JSON/logs, generated conceptual figures such as system overviews/pipelines/architectures/threat models, captions, artifact specs, source-data traceability, and paper-ready PDF/SVG/PNG/LaTeX exports. Do not use for prose-only paper writing, self-review, reviewer response, rebuttal drafting, or external literature-management workflows.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Knowledge base from the NIST Framework for Cyber-Physical Systems (SP 1500-201/202/203, v1.0, 2017). Use for engineering and analyzing cyber-physical systems (CPS) and IoT: the CPS Framework's aspect × facet grid (nine aspects of concern examined through conceptualization, realization, and assurance facets), cross-property trustworthiness risk management (safety/security/privacy/reliability/resilience together), data interoperability (syntactical/semantic/contextual, canonical models, identifiers, provenance), the timing aspect (time-interval classes, time domains, time-aware networking) and secure/resilient time (GNSS jamming/spoofing, PTP/NTP attacks, holdover, the clock-error model and Allan/MTIE metrics), plus the use-case requirements method. Bridges IT and OT under a clock. Scope limits: a 2017 living/draft document, thin on post-2017 standards and on detailed control catalogs; it names but does not reproduce ISO/IEC/IEEE 42010 and 15288 process text or permission-licensed third-party figures.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.
Designs Bayesian clinical trials including Phase I dose-finding (BOIN, CRM, EWOC, mTPI-2), meta-analytic-predictive (MAP) priors with robust mixtures for external data borrowing, EXNEX for basket trials, hierarchical models for safety AE (Berry-Berry), Bayesian platform trials (I-SPY 2, GBM AGILE, REMAP-CAP), and posterior probability stopping rules. Covers FDA Bayesian Devices Guidance (2010), FDA Bayesian Methodology in Drugs Draft (January 2026), BOIN Fit-for-Purpose qualification (December 2021), and Project Optimus dose-optimisation. Use when designing dose-finding studies, platform trials, or sensitivity analyses with informative priors.
한국어 요약은 준비 중입니다. 원문 설명을 표시하고 있습니다.